Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
Shin Y, Shin J, Moon S, Jin H, Kim S, Yang J, Cho S, Kim S, Lee M, Park Y, Kim M, Won H, Hong S, Kronbichler A, Koyanagi A, Jacob L, Smith L, Lee K, Suh D, Lee S, Yon D. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. The Lancet Rheumatology 2021, 3: e698-e706. PMID: 34179832, PMCID: PMC8213376, DOI: 10.1016/s2665-9913(21)00151-x.Peer-Reviewed Original ResearchCOVID-19-related deathsGeneral health examinationAutoimmune inflammatory rheumatic diseasesCOVID-19 outcomesHealth examinationDisease-modifying antirheumatic drugsIncreased likelihoodOdds ratioInflammatory rheumatic diseasesKorean National Health Insurance ServiceNational Health Insurance ServiceDoses of systemic corticosteroidsSARS-CoV-2 RT-PCR testAdjusted odds ratiosPositive SARS-CoV-2 testHealth Insurance ServiceICD-10 codesNationwide cohort studyHealth examination recordsSystemic corticosteroidsPositive SARS-CoV-2 PCR testCOVID-19 pandemicKorean nationwide cohortRheumatic diseasesPositive SARS-CoV-2 RT-PCR test
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply